Article Text

Download PDFPDF

1106 Molecular mechanisms of immunogenic cell death driven by PT-112
  1. Emma Guilbaud1,
  2. Takahiro Yamazaki1,
  3. Maria Congenie2,
  4. Christina Yim2,
  5. Tyler Ames2 and
  6. Lorenzo Galluzzi1
  1. 1Weill Cornell Medicine, New York, NY, USA
  2. 2Promontory Therapeutics Inc., New York, NY, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background PT-112 is a novel immunogenic small molecule1 under Phase II clinical development for cancer therapy.2–8 Besides mediating cytostatic and cytotoxic effects in numerous human and mouse cancer cells, PT-112 elicits various danger signals that are linked to immunogenic cell death (ICD) such as calreticulin exposure, as well as ATP and HMGB1 secretion.1 9–11 Accordingly, mouse cancer cells succumbing to PT-112 in vitro efficiently protect immunocompetent, tumor-naïve mice from challenge with living cancer cells of the same type.1 9 Moreover, PT-112 synergizes with PD-1 or PD-L1 blockade to control mouse tumors developing in immunologically competent hosts.1 9 This work focuses on elucidating the underlying mechanisms of PT-112-induced ICD.

Methods We harnessed a panel of human and mouse cell lines optionally engineered to lack specific genes involved in mitochondrial apoptosis (namely, Bcl2, Bax and Bak1) coupled with flow cytometry, immunoblotting, RT-PCR, immunofluorescence microscopy and clonogenic assays to determine the impact of reticular and mitochondrial events on the established ability of PT-112 to kill malignant cells in an immunogenic manner.1

Results In line with previous findings,10–13 PT-112 elicited eukaryotic translation initiation factor 2 subunit alpha (EIF2S1, best known as eIF2α) phosphorylation and mitochondrial dysfunction in malignant cells, a process that was accompanied by the release of interferogenic mitochondrial DNA (mtDNA)14 in the cytoplasm of PT-112 treated cells, and was differentially affected by the deletion of Bcl2, Bax, Bak1, or Bax plus Bak1. Similarly, the lack of Bcl2, Bax, Bak1, or Bax plus Bak1 had a differential impact on the ability of PT-112 to elicit early signs of mitochondrial apoptosis including reactive oxygen species (ROS) generation, mitochondrial transmembrane potential loss and ultimately plasma membrane permeabilization.

Conclusions ER stress and mitochondrial dysfunction appear to underlie the ability of PT-112 to drive ICD, the integrated stress response, and viral mimicry. This is in line with the well-established connections between ER stress and cytoplasmic nucleic acid sensing, which are pristine mechanisms of antiviral defense in mammalian cells, with the capacity of dying cells to emit immunostimulatory signals.15 Whether PT-112-driven stress also shifts the antigenic properties of cancer cells as a consequence of the accumulation of non-mutational neoantigens16 remains to be determined. Despite these and other open questions, PT-112 stands out as a powerful immunotherapeutic agent with promising clinical activity in patients with a variety of tumors1 under Phase II clinical development for cancer therapy.2–8


  1. Yamazaki T, et al. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9(1):1721810

  2. Karp DD, et al. Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 2022;49:101430.

  3. Bryce AH, et al. A phase 1b study of novel immunogenic cell death inducer PT-112 plus PD-L1 inhibitor avelumab in metastatic castrate-resistant prostate cancer (mCRPC) patients. Journal of Clinical Oncology. 2021;39(15_suppl):e17025-e17025. doi:10.1200/JCO.2021.39.15_suppl.e17025

  4. Kourelis T, et al. A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 2020;136(Supplement 1):9–10.

  5. Karp DD, et al. Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours. Annals of Oncology. 2020;31:S708.

  6. Imbimbo M, et al. A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (‘PAVE’) in advanced non-small cell lung cancer (NSCLC) patients (pts). Immuno-Oncology and Technology. 2022;16:100237.

  7. Swift S, et al. Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs). Journal of Clinical Oncology. 2023;41(16_suppl):e20647-e20647.

  8. Bryce AH, et al. A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 2023;41(6_suppl):TPS292-TPS292.

  9. Yamazaki T, Ames TD, Galluzzi L, Potent induction of immunogenic cell death by PT-112. Cancer Immunology Research. 2019;7(2_Supplement):B199-B199.

  10. Soler-Agesta R, et al. PT-112 induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines. Cancer Research. 2022;82(12_Supplement):1115–1115.

  11. Soler-Agesta R, et al. PT-112 Induces Mitochondrial Stress and Immunogenic Cell Death, Targeting Tumor Cells with Mitochondrial Deficiencies. Cancers (Basel). 2022;14(16):3851.

  12. Soler-Agesta R, et al. Characterization of differential metabolic phenotypes and PT-112-induced mitochondrial effects in human prostate cancer cells. European Journal of Cancer. 2022;174(Supplement 1):S39.

  13. Yamazaki T, et al. Immunologically relevant effects of PT-112 on cancer cell mitochondria. Journal for ImmunoTherapy of Cancer. 2022;10(Suppl 2):A1162-A1162.

  14. Yamazaki T, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nature Immunology. 2020;21(10):1160–1171.

  15. Kroemer G, et al. Immunogenic cell stress and death. Nature Immunology. 2022;23(4):487–500.

  16. Stern LJ, et al. Non-mutational neoantigens in disease. Nat Immunol. 2023; IN PRESS.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.